Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1767761

Cover Image

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1767761

Tuberculosis Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

PUBLISHED:
PAGES: 177 Pages
DELIVERY TIME: 2-5 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
PDF & Excel (Multi User License)
USD 7295
PDF & Excel (Corporate User License)
USD 8495

Add to Cart

Persistence Market Research has recently released a comprehensive report on the worldwide market for tuberculosis diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global tuberculosis diagnostics market from 2025 to 2032.

Key Insights:

  • Tuberculosis Diagnostics Market Size (2025E): USD 2.4 Billion
  • Projected Market Value (2032F): USD 3.5 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.5%

Tuberculosis Diagnostics Market - Report Scope:

Tuberculosis diagnostics play a critical role in the detection and management of tuberculosis (TB), a major infectious disease with significant global health implications. These diagnostic tools range from traditional smear microscopy to advanced molecular assays that offer rapid and precise detection of Mycobacterium tuberculosis and drug resistance patterns. The tuberculosis diagnostics market serves various healthcare settings, including hospitals, diagnostic laboratories, clinics, and point-of-care facilities, offering a diverse portfolio of tests such as culture-based methods, nucleic acid amplification tests (NAATs), tuberculin skin tests, interferon-gamma release assays (IGRAs), and radiographic examinations. Market growth is driven by the persistent global burden of tuberculosis, rising initiatives for early detection and disease control, and technological advancements improving test accuracy and turnaround times.

Market Growth Drivers:

The global tuberculosis diagnostics market is propelled by several key factors, including the sustained high incidence of tuberculosis, especially in developing regions with inadequate healthcare infrastructure. Growing global initiatives, such as the WHO's End TB Strategy, emphasize early diagnosis and effective treatment, fueling the demand for innovative diagnostic solutions. Technological advancements, including the development of rapid molecular diagnostics and automated platforms, enhance detection rates and facilitate drug-resistance profiling, enabling better patient management and outbreak control. Moreover, the increasing adoption of point-of-care testing solutions expands access to timely TB diagnosis, particularly in resource-limited settings, further driving market expansion.

Market Restraints:

Despite promising growth prospects, the tuberculosis diagnostics market faces challenges related to high costs of advanced diagnostic tests, limited laboratory infrastructure in low-income regions, and social stigma associated with TB, which can hinder timely testing and diagnosis. Complex regulatory requirements and lengthy approval processes for new diagnostic products also pose barriers for market entry and commercialization. Additionally, the variability in diagnostic accuracy of certain tests, particularly in latent TB detection, and the ongoing challenge of differentiating TB from other respiratory infections create hurdles in clinical decision-making, impacting market growth.

Market Opportunities:

The tuberculosis diagnostics market presents significant growth opportunities driven by emerging molecular technologies, integration of digital health tools, and rising public-private collaborations to improve TB detection and treatment outcomes. The increasing focus on multi-disease testing platforms that can detect TB alongside other respiratory infections enhances the commercial viability of diagnostic investments. Furthermore, rising funding from global health organizations and governments supports the development and deployment of affordable, rapid, and user-friendly TB diagnostics tailored for high-burden regions. Strategic partnerships, investments in research and development, and the launch of innovative diagnostic products, such as next-generation sequencing-based assays and portable NAAT devices, are essential to capitalize on these opportunities and sustain market leadership in the evolving TB diagnostics landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the tuberculosis diagnostics market globally?
  • Which diagnostic methods and applications are fueling TB testing adoption across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the tuberculosis diagnostics market?
  • Who are the key players contributing to the tuberculosis diagnostics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global tuberculosis diagnostics market?

Competitive Intelligence and Business Strategy:

These companies invest in R&D to develop advanced diagnostic solutions, including rapid molecular assays, automated testing systems, and portable diagnostic devices, addressing the diverse needs of high-burden regions and resource-limited settings. Partnerships with governments, non-governmental organizations, and global health agencies facilitate market access and promote adoption of novel TB diagnostics. Moreover, emphasis on cost-effective solutions, decentralized testing, and digital integration fosters market growth and supports public health efforts to reduce TB incidence and mortality rates worldwide.

Key Companies Profiled:

  • Abbott
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • BD
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Cepheid
  • DiaSorin S.p.A.
  • Hain Lifescience GmbH
  • Oxford Immunotec
  • Others

Tuberculosis Diagnostics Market Research Segmentation:

The tuberculosis diagnostics market encompasses a diverse range of tests, technologies, applications, and end-user segments, addressing various patient populations and clinical needs.

By Test Type

  • Nucleic Acid Testing
  • SMEAR Microscopy
  • Radiography Tests

By End User

  • Hospitals & Clinics
  • Diagnostics Centres
  • Others

By Region

  • North America
  • Latin America
  • Europe
  • South Asia & Oceania
  • East Asia
  • The Middle East & Africa
Product Code: PMRREP34779

Table of Contents

1. Executive Summary

  • 1.1. Global Tuberculosis Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Value Chain Analysis
  • 3.3. Regulatory Scenario
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Tuberculosis Diagnostics Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Tuberculosis Diagnostics Market Outlook: Test Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2024
    • 4.3.3. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
      • 4.3.3.1. Nucleic Acid Testing
      • 4.3.3.2. SMEAR Microscopy
      • 4.3.3.3. Radiography Tests
    • 4.3.4. Market Attractiveness Analysis: Test Type
  • 4.4. Global Tuberculosis Diagnostics Market Outlook: End User
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
    • 4.4.3. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.4.3.1. Hospitals & Clinics
      • 4.4.3.2. Diagnostics Centres
      • 4.4.3.3. Others
    • 4.4.4. Market Attractiveness Analysis: End User

5. Global Tuberculosis Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Tuberculosis Diagnostics Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Test Type
    • 6.2.3. By End User
  • 6.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 6.4.1. Nucleic Acid Testing
    • 6.4.2. SMEAR Microscopy
    • 6.4.3. Radiography Tests
  • 6.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.5.1. Hospitals & Clinics
    • 6.5.2. Diagnostics Centres
    • 6.5.3. Others
  • 6.6. Market Attractiveness Analysis

7. Europe Tuberculosis Diagnostics Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Test Type
    • 7.2.3. By End User
  • 7.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Rest of Europe
  • 7.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 7.4.1. Nucleic Acid Testing
    • 7.4.2. SMEAR Microscopy
    • 7.4.3. Radiography Tests
  • 7.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.5.1. Hospitals & Clinics
    • 7.5.2. Diagnostics Centres
    • 7.5.3. Others
  • 7.6. Market Attractiveness Analysis

8. East Asia Tuberculosis Diagnostics Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Test Type
    • 8.2.3. By End User
  • 8.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 8.4.1. Nucleic Acid Testing
    • 8.4.2. SMEAR Microscopy
    • 8.4.3. Radiography Tests
  • 8.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.5.1. Hospitals & Clinics
    • 8.5.2. Diagnostics Centres
    • 8.5.3. Others
  • 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Tuberculosis Diagnostics Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Test Type
    • 9.2.3. By End User
  • 9.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 9.4.1. Nucleic Acid Testing
    • 9.4.2. SMEAR Microscopy
    • 9.4.3. Radiography Tests
  • 9.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.5.1. Hospitals & Clinics
    • 9.5.2. Diagnostics Centres
    • 9.5.3. Others
  • 9.6. Market Attractiveness Analysis

10. Latin America Tuberculosis Diagnostics Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Test Type
    • 10.2.3. By End User
  • 10.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 10.4.1. Nucleic Acid Testing
    • 10.4.2. SMEAR Microscopy
    • 10.4.3. Radiography Tests
  • 10.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.5.1. Hospitals & Clinics
    • 10.5.2. Diagnostics Centres
    • 10.5.3. Others
  • 10.6. Market Attractiveness Analysis

11. Middle East & Africa Tuberculosis Diagnostics Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Test Type
    • 11.2.3. By End User
  • 11.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 11.4.1. Nucleic Acid Testing
    • 11.4.2. SMEAR Microscopy
    • 11.4.3. Radiography Tests
  • 11.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.5.1. Hospitals & Clinics
    • 11.5.2. Diagnostics Centres
    • 11.5.3. Others
  • 11.6. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Abbott
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. QIAGEN
    • 12.3.3. Thermo Fisher Scientific Inc.
    • 12.3.4. BD
    • 12.3.5. F. Hoffmann-La Roche AG
    • 12.3.6. Hologic, Inc.
    • 12.3.7. Cepheid
    • 12.3.8. DiaSorin S.p.A.
    • 12.3.9. Hain Lifescience GmbH
    • 12.3.10. Oxford Immunotec
    • 12.3.11. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!